149 related articles for article (PubMed ID: 37466990)
1. Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping.
Ioannou A; Patel RK; Martinez-Naharro A; Razvi Y; Porcari A; Rauf MU; Bolhuis RE; Fernando-Sayers J; Virsinskaite R; Bandera F; Kotecha T; Venneri L; Knight D; Manisty C; Moon J; Lachmann H; Whelan C; Kellman P; Hawkins PN; Gillmore JD; Wechalekar A; Fontana M
JAMA Cardiol; 2023 Sep; 8(9):848-852. PubMed ID: 37466990
[TBL] [Abstract][Full Text] [Related]
2. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
[TBL] [Abstract][Full Text] [Related]
3. T1 mapping and survival in systemic light-chain amyloidosis.
Banypersad SM; Fontana M; Maestrini V; Sado DM; Captur G; Petrie A; Piechnik SK; Whelan CJ; Herrey AS; Gillmore JD; Lachmann HJ; Wechalekar AD; Hawkins PN; Moon JC
Eur Heart J; 2015 Jan; 36(4):244-51. PubMed ID: 25411195
[TBL] [Abstract][Full Text] [Related]
4. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
5. A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis.
Chamling B; Bietenbeck M; Drakos S; Korthals D; Vehof V; Stalling P; Meier C; Yilmaz A
Sci Rep; 2022 Dec; 12(1):21755. PubMed ID: 36526658
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Volume Associates With Outcomes More Strongly Than Native or Post-Contrast Myocardial T1.
Treibel TA; Fridman Y; Bering P; Sayeed A; Maanja M; Frojdh F; Niklasson L; Olausson E; Wong TC; Kellman P; Miller CA; Moon JC; Ugander M; Schelbert EB
JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 1):44-54. PubMed ID: 31103587
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
Thavendiranathan P; Shalmon T; Fan CS; Houbois C; Amir E; Thevakumaran Y; Somerset E; Malowany JM; Urzua-Fresno C; Yip P; McIntosh C; Sussman MS; Brezden-Masley C; Yan AT; Koch CA; Spiller N; Abdel-Qadir H; Power C; Hanneman K; Wintersperger BJ
JAMA Cardiol; 2023 Jun; 8(6):524-534. PubMed ID: 37043251
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of Hepatic T1-Mapping and Extracellular Volume Quantification on Routine Cardiac Magnetic Resonance Imaging in Patients with Infiltrative and Systemic Disorders.
Dolan RS; Stillman AE; Davarpanah AH
Acad Radiol; 2022 Apr; 29 Suppl 4():S100-S109. PubMed ID: 34702675
[TBL] [Abstract][Full Text] [Related]
9. Tracking Multiorgan Treatment Response in Systemic AL-Amyloidosis With Cardiac Magnetic Resonance Derived Extracellular Volume Mapping.
Ioannou A; Patel RK; Martinez-Naharro A; Razvi Y; Porcari A; Hutt DF; Bandera F; Kotecha T; Venneri L; Chacko L; Massa P; Hanger M; Knight D; Manisty C; Moon J; Quarta C; Lachmann H; Whelan C; Kellman P; Hawkins PN; Gillmore JD; Wechelakar A; Fontana M
JACC Cardiovasc Imaging; 2023 Aug; 16(8):1038-1052. PubMed ID: 37178079
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).
Puntmann VO; Carerj ML; Wieters I; Fahim M; Arendt C; Hoffmann J; Shchendrygina A; Escher F; Vasa-Nicotera M; Zeiher AM; Vehreschild M; Nagel E
JAMA Cardiol; 2020 Nov; 5(11):1265-1273. PubMed ID: 32730619
[TBL] [Abstract][Full Text] [Related]
11. Regional Amyloid Burden Differences Evaluated Using Quantitative Cardiac MRI in Patients with Cardiac Amyloidosis.
Kim JY; Hong YJ; Han K; Lee HJ; Hur J; Kim YJ; Choi BW
Korean J Radiol; 2021 Jun; 22(6):880-889. PubMed ID: 33686816
[TBL] [Abstract][Full Text] [Related]
12. Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain.
Cao Y; Zeng W; Cui Y; Kong X; Wang M; Yu J; Zhang S; Song J; Yan X; Greiser A; Shi H
Cardiovasc Diabetol; 2018 Jan; 17(1):7. PubMed ID: 29301529
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of native T1 and extracellular volume in patients with immunoglubin light-chain amyloidosis.
Liu Y; Wang L; Zhu J; Chen M; Zhu M; Dai Y; Hu C
BMC Cardiovasc Disord; 2024 Feb; 24(1):112. PubMed ID: 38365569
[TBL] [Abstract][Full Text] [Related]
14. Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping.
Ntusi NAB; Piechnik SK; Francis JM; Ferreira VM; Matthews PM; Robson MD; Wordsworth PB; Neubauer S; Karamitsos TD
JACC Cardiovasc Imaging; 2015 May; 8(5):526-536. PubMed ID: 25890584
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and Prognostic Value of Non-late Gadolinium Enhancement Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis.
Briasoulis A; Lama N; Rempakos A; Theodorakakou F; Stamatelopoulos K; Dimopoulos MA; Kelekis N; Kastritis E
Curr Probl Cardiol; 2023 Apr; 48(4):101573. PubMed ID: 36586704
[TBL] [Abstract][Full Text] [Related]
16. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.
Barison A; Aquaro GD; Pugliese NR; Cappelli F; Chiappino S; Vergaro G; Mirizzi G; Todiere G; Passino C; Masci PG; Perfetto F; Emdin M
J Intern Med; 2015 May; 277(5):605-14. PubMed ID: 25346163
[TBL] [Abstract][Full Text] [Related]
17. Myocardial extracellular volume quantification in cardiac amyloidosis: a comparative study between cardiac computed tomography and magnetic resonance imaging.
Hayashi H; Oda S; Kidoh M; Yamaguchi S; Yoshimura F; Takashio S; Usuku H; Nagayama Y; Nakaura T; Ueda M; Tsujita K; Hirai T
Eur Radiol; 2024 Feb; 34(2):1016-1025. PubMed ID: 37597032
[TBL] [Abstract][Full Text] [Related]
18. 3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis.
Liu Y; Zhu J; Chen M; Wang L; Zhu M; Weng Z; Hu C
Ann Transl Med; 2022 Jul; 10(14):794. PubMed ID: 35965812
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients.
Yue X; Yang L; Wang R; Chan Q; Yang Y; Wu X; Ruan X; Zhang Z; Wei Y; Wang F
Front Cardiovasc Med; 2022; 9():1017097. PubMed ID: 36330005
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
